- STAT+: Longevity, wellness physicians named to panel advising FDA on peptidesThe panel will soon consider whether to relax restrictions on certain peptides.STAT · 27d ago↗ source
- Zymeworks CEO on why the Theravance deal is value for moneyOn the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out of steam, having twice downsized and been hit with repeated ...Endpoints · 27d ago↗ source
- BioCryst ends internal discovery programs, will close Alabama research facilityBioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally. The company announced a plan to discontinue its internal di…Endpoints